Home › Funds › Octagon Capital Advisors LP › OCUL
Octagon Capital Advisors LP position in OCUL
OCULAR THERAPEUTIX INC · Health Care
Octagon Capital Advisors LP reported holding 599,900 shares of OCUL (OCULAR THERAPEUTIX INC) in its Q3 2026 13F filing — a position valued at US$4.6M, representing 0.61% of its reported portfolio and ranking #21 among its reported holdings. Octagon Capital Advisors LP has disclosed OCUL holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Octagon Capital Advisors LP's OCUL position evolved
Octagon Capital Advisors LP first disclosed a stake in OCUL in Q1 2024 at 2,425,000 shares (US$22.1M). The position peaked in Q4 2025 at 2,623,600 shares, worth US$31.9M. Across 11 filings, Octagon Capital Advisors LP increased the stake 2 time(s), trimmed it 2 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 599,900 shares valued at US$4.6M — a reduction of -1,475,100 shares quarter over quarter.. Notable position changes include a 34% trim in Q2 2026 (shares fell 22% over the following quarter), a 71% trim in Q3 2026 (shares fell 22% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 2.42M | $22.07M | New |
| Q2 2024 | 2.42M | $16.59M | Hold |
| Q3 2024 | 2.42M | $21.10M | Hold |
| Q4 2024 | 2.42M | $20.71M | Hold |
| Q1 2025 | 2.42M | $17.78M | Hold |
| Q2 2025 | 2.42M | $22.50M | Hold |
| Q3 2025 | 2.62M | $30.67M | Add |
| Q4 2025 | 2.62M | $31.85M | Hold |
| Q1 2026 | 3.17M | $26.82M | Add |
| Q2 2026 | 2.08M | $20.38M | Reduce |
| Q3 2026 | 599.90K | $4.60M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About OCUL and 13F data
OCUL (OCULAR THERAPEUTIX INC) is a Health Care company. 30 other funds we track also report a position in OCUL — the largest reported positions include Deep Track Capital, LP (US$168.3M), SUMMER ROAD LLC (US$95.6M), Avoro Capital Advisors LLC (US$95.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding OCUL
- Deep Track Capital, LP 21.94M sh · $168.28M · Q3 2026
- SUMMER ROAD LLC 12.46M sh · $95.59M · Q3 2026
- Avoro Capital Advisors LLC 12.38M sh · $94.96M · Q3 2026
- Venrock Adviser, LLC 10.35M sh · $79.36M · Q3 2026
- Logos Global Management LP 6.00M sh · $46.02M · Q3 2026
- DELTEC ASSET MANAGEMENT LLC 2.62M sh · $20.12M · Q3 2026
- Defilade Capital Management, L.P. 2.28M sh · $17.45M · Q3 2026
More on Octagon Capital Advisors LP
FAQ
How long has Octagon Capital Advisors LP held OCUL?
Octagon Capital Advisors LP has disclosed OCUL holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
What is Octagon Capital Advisors LP's current position in OCUL?
As of Q3 2026, Octagon Capital Advisors LP holds 599.90K shares of OCUL (OCULAR THERAPEUTIX INC), valued at $4.60M, representing 0.61% of its reported portfolio and ranking #21.
Has Octagon Capital Advisors LP been buying or selling OCUL?
In the latest 13F filing (Q3 2026), Octagon Capital Advisors LP reduced its position in OCUL. The position peaked in Q4 2025 at 2.62M shares.
Which other funds hold OCUL?
Other major institutional holders of OCUL include Deep Track Capital, LP, SUMMER ROAD LLC, Avoro Capital Advisors LLC, among 30 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.